Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-22 00:14 | 2026-01-20 | APLS | Apellis Pharmaceuticals Inc. | Francois Cedric | Director, Officer | SELL | $19.79 | 8,182 | $161,946 | 313,237 |
| 2026-01-22 00:12 | 2026-01-20 | APLS | Apellis Pharmaceuticals Inc. | Nicholson Nur | Officer | SELL | $19.79 | 2,203 | $43,604 | 78,843 |
| 2026-01-22 00:10 | 2026-01-20 | APLS | Apellis Pharmaceuticals Inc. | Sullivan Timothy Eugene | Officer | SELL | $19.79 | 2,892 | $57,241 | 104,188 |
| 2026-01-22 00:08 | 2026-01-20 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $19.79 | 2,475 | $48,987 | 96,363 |
| 2026-01-22 01:17 | 2026-01-20 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | Officer | SELL | $2.88 | 1,689 | $4,868 | 384,216 |
| 2026-01-22 01:17 | 2026-01-20 | PTGX | Protagonist Therapeutics, Inc | MOLINA ARTURO MD | Officer | SELL | $82.48 | 9,514 | $784,715 | 97,266 |
| 2026-01-22 01:15 | 2026-01-20 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer | SELL | $82.48 | 8,588 | $708,338 | 78,077 |
| 2026-01-22 00:30 | 2026-01-21 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Director | SELL | $5.23 | 13,500 | $70,574 | 48,752 |
| 2026-01-22 03:17 | 2026-01-20 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $3.04 | 4,000 | $12,140 | 0 |
| 2026-01-22 00:05 | 2026-01-20 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer | OPT+S | $27.34 | 10,000 | $273,420 | 90,270 |
| 2026-01-22 01:16 | 2026-01-20 | PTGX | Protagonist Therapeutics, Inc | PATEL DINESH V PH D | Director, Officer | SELL | $82.48 | 34,438 | $2,840,446 | 580,505 |
| 2026-01-21 04:18 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | Kordasiewicz Holly B. | Officer | OPT+S | $75.66 | 4,141 | $313,308 | 14,718 |
| 2026-01-21 04:18 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer | OPT+S | $75.95 | 8,353 | $634,410 | 26,518 |
| 2026-01-21 00:52 | 2026-01-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Director, Officer | SELL | $18.02 | 149 | $2,685 | 213,992 |
| 2026-01-21 04:18 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | Birchler Brian | Officer | OPT+S | $75.11 | 8,480 | $636,933 | 60,435 |
| 2026-01-20 18:29 | 2025-10-17 | MYNZ | MAINZ BIOMED N.V. | Donahue Kevin Michael | 10% owner | BUY | $1.51 | 685,000 | $1,034,350 | 685,000 |
| 2026-01-21 00:30 | 2026-01-12 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | Officer | SELL | $28.52 | 8,000 | $228,186 | 154,981 |
| 2026-01-21 04:21 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | Schneider Eugene | Officer | OPT+S | $75.59 | 9,302 | $703,138 | 63,890 |
| 2026-01-21 04:18 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | Baroldi Joseph | Officer | OPT+S | $75.75 | 8,056 | $610,277 | 4,772 |
| 2026-01-21 01:00 | 2026-01-16 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $39.52 | 20,000 | $790,346 | 40,000 |
| 2026-01-21 04:18 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | Jenne Kyle | Officer | OPT+S | $75.96 | 1,823 | $138,475 | 16,389 |
| 2026-01-21 04:21 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | Swayze Eric | Officer | OPT+S | $75.34 | 9,933 | $748,383 | 318 |
| 2026-01-21 01:38 | 2026-01-15 | NKTX | Nkarta, Inc. | Mahmood Nadir | Officer | SELL | $2.07 | 5,649 | $11,693 | 167,727 |
| 2026-01-20 22:09 | 2026-01-16 | XCUR | EXICURE, INC. | Exicure HiTron Inc. | 10% owner | SELL | $4.50 | 734,747 | $3,306,362 | 1,857,314 |
| 2026-01-21 04:39 | 2026-01-15 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | Officer | SELL | $35.92 | 20,961 | $752,833 | 0 |
| 2026-01-21 04:33 | 2026-01-20 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $32.10 | 416 | $13,354 | 50,437 |
| 2026-01-21 05:46 | 2026-01-15 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Cohen Joshua B | Director, Officer | OPT+S | $13.59 | 138,167 | $1,878,090 | 3,379,465 |
| 2026-01-21 05:46 | 2026-01-15 | AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | Klee Justin B. | Director, Officer | OPT+S | $13.59 | 138,188 | $1,877,574 | 3,379,398 |
| 2026-01-21 03:19 | 2026-01-16 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Director | SELL | $12.00 | 6,700 | $80,431 | 213,072 |
| 2026-01-21 04:20 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. | Officer | OPT+S | $75.84 | 9,191 | $697,045 | 66,171 |
| 2026-01-21 03:57 | 2026-01-20 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $18.42 | 3,760 | $69,273 | 50,897 |
| 2026-01-21 04:20 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | Monia Brett P | Director, Officer | OPT+S | $74.82 | 44,034 | $3,294,624 | 224,683 |
| 2026-01-20 17:17 | 2026-01-15 | IMRX | Immuneering Corp | Schall Thomas J. | Director | BUY | $4.67 | 21,645 | $101,041 | 74,530 |
| 2026-01-21 01:39 | 2026-01-15 | NKTX | Nkarta, Inc. | HASTINGS PAUL J | Director, Officer | SELL | $2.07 | 26,046 | $53,915 | 390,023 |
| 2026-01-21 01:58 | 2026-01-20 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Kelley Shannon T | Officer | SELL | $497.36 | 692 | $344,173 | 8,481 |
| 2026-01-21 01:46 | 2026-01-20 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca | Director | SELL | $490.77 | 2,238 | $1,098,343 | 453,351 |
| 2026-01-21 00:07 | 2026-01-16 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.54 | 38,782 | $20,942 | 2,159,860 |
| 2026-01-21 00:30 | 2026-01-16 | ONCY | ONCOLYTICS BIOTECH INC | Seizinger Bernd R. | Director | BUY | $1.04 | 100,000 | $103,770 | 466,991 |
| 2026-01-21 00:30 | 2026-01-16 | UTHR | UNITED THERAPEUTICS Corp | MALCOLM JAN | Director | SELL | $460.98 | 50 | $23,049 | 320 |
| 2026-01-21 04:18 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | HOUGEN ELIZABETH L | Officer | OPT+S | $75.22 | 12,922 | $971,993 | 126,307 |
| 2026-01-21 04:18 | 2026-01-16 | IONS | IONIS PHARMACEUTICALS INC | BENNETT C FRANK | Officer | OPT+S | $75.15 | 8,977 | $674,622 | 94,757 |
| 2026-01-21 00:33 | 2026-01-15 | DVAX | Dynavax Technologies Corporation | Novack David F | Officer | OPT+S | $15.64 | 114,000 | $1,782,960 | 63,344 |
| 2026-01-17 00:06 | 2026-01-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $26.84 | 8,500 | $228,132 | 395,575 |
| 2026-01-16 23:42 | 2025-10-17 | MYNZ | MAINZ BIOMED N.V. | Donahue Kevin Michael | 10% owner | BUY | $402,000.00 | 643,850 | $258,827,700,000 | 643,850 |
| 2026-01-17 01:22 | 2026-01-15 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | Director, Officer | OPT+S | $37.07 | 68,749 | $2,548,601 | 288,976 |
| 2026-01-16 19:16 | 2026-01-13 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $5.01 | 58,289 | $292,185 | 650,298 |
| 2026-01-17 00:07 | 2026-01-15 | IMRX | Immuneering Corp | Hall Brett Matthew | Officer | BUY | $4.57 | 2,298 | $10,502 | 376,496 |
| 2026-01-17 00:02 | 2026-01-14 | ACRV | Acrivon Therapeutics Inc. | Blume-Jensen Peter | Director, Officer | BUY | $1.68 | 49,000 | $82,124 | 2,095,771 |
| 2026-01-17 00:01 | 2026-01-14 | ACRV | Acrivon Therapeutics Inc. | Levy Adam D. | Officer | BUY | $1.70 | 8,832 | $14,999 | 20,983 |
| 2026-01-17 01:26 | 2026-01-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Officer | OPT+S | $31.81 | 7,000 | $222,704 | 1,518 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.